[HLA-B*5701 and abacavir hypersensitivity reaction].
A potentially life-threatening hypersensitive reaction occurs in association with initiation of HIV nucleoside analogue abacavir therapy in 4 to 8% of patients. Preliminary studies appear to confirm the role of the immune system in abacavir hypersensitivity. The reaction is possibly the result of presentation of drug peptides onto HLA, that may induce a pathogenic T-cell response. Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele and prospective HLA-B*5701 genetic screening has now been instituted in clinical practice to reduce the risk of hypersensitivity reaction.
Servonnet
A
A
Laboratoire de biochimie, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 94163 Saint-Mandé cedex, France. a_servonnet@yahoo.fr
Leclercq
E
E
Delacour
H
H
Ceppa
F
F
D000483:Alleles; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000276:immunology; D017951:Antigen Presentation; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology / Q000517:prevention & control; D005787:Gene Frequency; D005805:Genes, MHC Class I; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015235:HLA-B Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D010446:Peptide Fragments / Q000276:immunology; D016133:Polymerase Chain Reaction; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000276:immunology; D017422:Sequence Analysis, DNA; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D054303:HIV Reverse Transcriptase; D015235:HLA-B Antigens; D010446:Peptide Fragments; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir